{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T20:17:34Z","timestamp":1791145054693,"version":"4.1.0"},"reference-count":129,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2013,7,1]],"date-time":"2013-07-01T00:00:00Z","timestamp":1372636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,7,1]],"date-time":"2013-07-01T00:00:00Z","timestamp":1372636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,10]],"date-time":"2022-12-10T00:00:00Z","timestamp":1670630400000},"content-version":"vor","delay-in-days":3449,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2013,7]]},"DOI":"10.1111\/jth.12265","type":"journal-article","created":{"date-parts":[[2013,4,19]],"date-time":"2013-04-19T08:27:01Z","timestamp":1366360021000},"page":"1215-1227","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":69,"title":["Thrombotic complications of myeloproliferative neoplasms: risk assessment and risk\u2010guided management"],"prefix":"10.1016","volume":"11","author":[{"given":"A.","family":"Casini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Fontana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.P.","family":"Lecompte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1111\/jth.12265_bb0010","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1200\/JCO.2010.29.8711","article-title":"Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies","volume":"29","author":"Tefferi","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1111\/jth.12265_bb0015","series-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow","year":"2008"},{"key":"10.1111\/jth.12265_bb0020","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1038\/leu.2012.12","article-title":"How to manage children and young adults with myeloproliferative neoplasms","volume":"26","author":"Barbui","year":"2012","journal-title":"Leukemia"},{"key":"10.1111\/jth.12265_bb0025","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1200\/JCO.2012.42.1925","article-title":"Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: a population\u2010based study","volume":"30","author":"Hultcrantz","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1111\/jth.12265_bb0030","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/leu.2008.72","article-title":"Life expectancy and prognostic factors in the classic BCR\/ABL\u2010negative myeloproliferative disorders","volume":"22","author":"Cervantes","year":"2008","journal-title":"Leukemia"},{"key":"10.1111\/jth.12265_bb0035","doi-asserted-by":"crossref","first-page":"5710","DOI":"10.1182\/blood-2010-07-293761","article-title":"Essential thrombocythemia versus early primary myelofibrosis: a multicenter study to validate the WHO classification","volume":"117","author":"Thiele","year":"2011","journal-title":"Blood"},{"key":"10.1111\/jth.12265_bb0040","doi-asserted-by":"crossref","first-page":"656","DOI":"10.7326\/0003-4819-123-9-199511010-00003","article-title":"Polycythemia vera: the natural history of 1213 patients followed for 20\u00a0years","volume":"123","year":"1995","journal-title":"Ann Intern Med"},{"key":"10.1111\/jth.12265_bb0045","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1200\/JCO.2005.07.062","article-title":"Vascular and neoplastic risk in a large cohort of patients with polycythemia vera","volume":"23","author":"Marchioli","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1111\/jth.12265_bb0050","doi-asserted-by":"crossref","first-page":"5857","DOI":"10.1182\/blood-2011-02-339002","article-title":"Risk factors for arterial and venous thrombosis in WHO\u2010defined essential thrombocythemia: an international study of 891 patients","volume":"117","author":"Carobbio","year":"2011","journal-title":"Blood"},{"key":"10.1111\/jth.12265_bb0055","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/sj.leu.2404048","article-title":"Frequency and risk factors for thrombosis in idiopathic myelofibrosis: analysis in a series of 155 patients from a single institution","volume":"20","author":"Cervantes","year":"2006","journal-title":"Leukemia"},{"key":"10.1111\/jth.12265_bb0060","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1182\/blood-2009-08-238956","article-title":"Thrombosis in primary myelofibrosis: incidence and risk factors","volume":"115","author":"Barbui","year":"2010","journal-title":"Blood"},{"key":"10.1111\/jth.12265_bb0065","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1046\/j.1365-2141.1998.01021.x","article-title":"No treatment for low\u2010risk thrombocythaemia: results from a prospective study","volume":"103","author":"Ruggeri","year":"1998","journal-title":"Br J Haematol"},{"key":"10.1111\/jth.12265_bb0070","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/sj.leu.2401270","article-title":"Major vascular complications in essential thrombocythemia: a study of the predictive factors in a series of 148 patients","volume":"13","author":"Besses","year":"1999","journal-title":"Leukemia"},{"key":"10.1111\/jth.12265_bb0075","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1034\/j.1600-0609.2000.90236.x","article-title":"Incidence, clinical features and outcome of essential thrombocythaemia in a well defined geographical area","volume":"65","author":"Jensen","year":"2000","journal-title":"Eur J Haematol"},{"key":"10.1111\/jth.12265_bb0080","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.amjmed.2004.06.032","article-title":"Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia","volume":"117","author":"Passamonti","year":"2004","journal-title":"Am J Med"},{"key":"10.1111\/jth.12265_bb0085","doi-asserted-by":"crossref","first-page":"159","DOI":"10.4065\/81.2.159","article-title":"Essential thrombocythemia beyond the first decade: life expectancy, long\u2010term complication rates, and prognostic factors","volume":"81","author":"Wolansky","year":"2006","journal-title":"Mayo Clin Proc"},{"key":"10.1111\/jth.12265_bb0090","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1038\/sj.leu.2404693","article-title":"Essential thrombocythemia in young individuals: frequency and risk factors for vascular events and evolution to myelofibrosis in 126 patients","volume":"21","author":"Alvarez\u2010Larran","year":"2007","journal-title":"Leukemia"},{"key":"10.1111\/jth.12265_bb0095","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1182\/blood-2006-12-064287","article-title":"Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia","volume":"110","author":"Vannucchi","year":"2007","journal-title":"Blood"},{"key":"10.1111\/jth.12265_bb0100","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.3324\/haematol.13346","article-title":"Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients","volume":"93","author":"Passamonti","year":"2008","journal-title":"Haematologica"},{"key":"10.1111\/jth.12265_bb0105","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/ajh.21360","article-title":"Long\u2010term follow\u2010up of 386 consecutive patients with essential thrombocythemia: safety of cytoreductive therapy","volume":"84","author":"Palandri","year":"2009","journal-title":"Am J Hematol"},{"key":"10.1111\/jth.12265_bb0110","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1182\/blood-2010-01-263319","article-title":"Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low\u2010risk essential thrombocythemia","volume":"116","author":"Alvarez\u2010Larran","year":"2010","journal-title":"Blood"},{"key":"10.1111\/jth.12265_bb0115","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1038\/leu.2010.5","article-title":"Leukocytosis is associated with poor survival but not with increased risk of thrombosis in essential thrombocythemia: a population\u2010based study of 311 patients","volume":"24","author":"Girodon","year":"2010","journal-title":"Leukemia"},{"key":"10.1111\/jth.12265_bb0120","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1200\/JCO.2010.34.5298","article-title":"Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study","volume":"29","author":"Barbui","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1111\/jth.12265_bb0125","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1002\/ajh.23217","article-title":"Leukocytosis as an important risk factor for arterial thrombosis in WHO\u2010defined early\/prefibrotic myelofibrosis: an international study of 264 patients","volume":"87","author":"Buxhofer\u2010Ausch","year":"2012","journal-title":"Am J Hematol"},{"key":"10.1111\/jth.12265_bb0130","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1182\/blood-2012-01-407981","article-title":"Disease characteristics and clinical outcome in young adults with essential thrombocythemia versus early\/prefibrotic primary myelofibrosis","volume":"120","author":"Barbui","year":"2012","journal-title":"Blood"},{"key":"10.1111\/jth.12265_bb0135","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1182\/blood-2011-08-371328","article-title":"Thrombocythemia and polycythemia in patients younger than 20\u00a0years at diagnosis: clinical and biologic features, treatment, and long\u2010term outcome","volume":"119","author":"Giona","year":"2012","journal-title":"Blood"},{"key":"10.1111\/jth.12265_bb0140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/ajh.10153","article-title":"Factor\u00a0V Leiden mutation carriership and venous thromboembolism in polycythemia vera and essential thrombocythemia","volume":"71","author":"Ruggeri","year":"2002","journal-title":"Am J Hematol"},{"key":"10.1111\/jth.12265_bb0145","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1177\/107602969900500210","article-title":"Aspirin seems as effective as myelosuppressive agents in the prevention of rethrombosis in essential thrombocythemia","volume":"5","author":"Randi","year":"1999","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1111\/jth.12265_bb0150","doi-asserted-by":"crossref","first-page":"372","DOI":"10.3324\/haematol.12053","article-title":"Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments","volume":"93","author":"De Stefano","year":"2008","journal-title":"Haematologica"},{"key":"10.1111\/jth.12265_bb0155","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.thromres.2003.12.015","article-title":"Oral anticoagulants as secondary prophylaxis of thrombosis in patients with polycythemia vera: a retrospective analysis of 15 patients","volume":"112","author":"Bachleitner\u2010Hofmann","year":"2003","journal-title":"Thromb Res"},{"key":"10.1111\/jth.12265_bb0160","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1182\/blood-2006-08-042515","article-title":"Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera","volume":"109","author":"Landolfi","year":"2007","journal-title":"Blood"},{"key":"10.1111\/jth.12265_bb0165","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/j.1600-0609.2006.00715.x","article-title":"Abdominal vein thrombosis in essential thrombocythemia: prevalence, clinical correlates, and prognostic implications","volume":"77","author":"Gangat","year":"2006","journal-title":"Eur J Haematol"},{"key":"10.1111\/jth.12265_bb0170","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1111\/j.1538-7836.2007.02424.x","article-title":"Incidence of the JAK2 V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders","volume":"5","author":"De Stefano","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.12265_bb0175","first-page":"509","article-title":"Polycythemia vera: gender\u2010related phenotypic differences","volume":"12","author":"Landolfi","year":"2011","journal-title":"Intern Emerg Med"},{"key":"10.1111\/jth.12265_bb0180","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1160\/TH07-09-0570","article-title":"Venous thrombosis in oral contraceptive users and the presence of the JAK2 V617F mutation","volume":"99","author":"Grandone","year":"2008","journal-title":"Thromb Haemost"},{"key":"10.1111\/jth.12265_bb0185","first-page":"1712","article-title":"Myeloproliferative disease in the pathogenesis and survival of Budd\u2013Chiari syndrome","volume":"91","author":"Smalberg","year":"2006","journal-title":"Haematologica"},{"key":"10.1111\/jth.12265_bb0190","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1002\/hep.21435","article-title":"Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis","volume":"44","author":"Primignani","year":"2006","journal-title":"Hepatology"},{"key":"10.1111\/jth.12265_bb0195","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1053\/j.gastro.2006.04.008","article-title":"Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd\u2013Chiari syndrome","volume":"130","author":"Patel","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1111\/jth.12265_bb0200","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1111\/j.1538-7836.2007.02384.x","article-title":"JAK2 V617F is specifically associated with idiopathic splanchnic vein thrombosis","volume":"5","author":"Regina","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.12265_bb0205","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1309\/JA1WD8JNVLGYNQYE","article-title":"JAK2 V617F mutation in patients with catastrophic intra\u2010abdominal thromboses","volume":"127","author":"McMahon","year":"2007","journal-title":"Am J Clin Pathol"},{"key":"10.1111\/jth.12265_bb0210","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1538-7836.2006.02277.x","article-title":"The JAK2 V617F mutation frequently occurs in patients with portal and mesenteric venous thrombosis","volume":"5","author":"Colaizzo","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.12265_bb0215","doi-asserted-by":"crossref","first-page":"4922","DOI":"10.1182\/blood-2007-11-125328","article-title":"The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases","volume":"111","author":"Kiladjian","year":"2008","journal-title":"Blood"},{"key":"10.1111\/jth.12265_bb0220","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1160\/TH08-07-0451","article-title":"Prevalence of the JAK2 V617F mutation associated with splanchnic vein thrombosis. A 10\u2010year retrospective study","volume":"101","author":"Tondeur","year":"2009","journal-title":"Thromb Haemost"},{"key":"10.1111\/jth.12265_bb0225","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1309\/AJCP7VO4HAIZYATP","article-title":"JAK2 mutations across a spectrum of venous thrombosis cases","volume":"134","author":"Shetty","year":"2010","journal-title":"Am J Clin Pathol"},{"key":"10.1111\/jth.12265_bb0230","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.jhep.2012.07.034","article-title":"Pregnancy in women with portal vein thrombosis: results of a multicentric European study on maternal and fetal management and outcome","volume":"57","author":"Hoekstra","year":"2012","journal-title":"J Hepatol"},{"key":"10.1111\/jth.12265_bb0235","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1007\/s11239-012-0738-2","article-title":"The clinical significance of JAK2V617F mutation for Philadelphia\u2010negative chronic myeloproliferative neoplasms in patients with splanchnic vein thrombosis","volume":"34","author":"Yonal","year":"2012","journal-title":"J Thromb Thrombolysis"},{"key":"10.1111\/jth.12265_bb0240","doi-asserted-by":"crossref","first-page":"2778","DOI":"10.1007\/s10620-008-0225-y","article-title":"JAK2V617F mutation in patients with portal vein thrombosis","volume":"53","author":"Bayraktar","year":"2008","journal-title":"Dig Dis Sci"},{"key":"10.1111\/jth.12265_bb0245","doi-asserted-by":"crossref","first-page":"167","DOI":"10.7326\/0003-4819-151-3-200908040-00004","article-title":"Etiology, management, and outcome of the Budd\u2013Chiari syndrome","volume":"151","author":"Darwish Murad","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1111\/jth.12265_bb0250","first-page":"108","article-title":"Budd Chiari syndrome and V617F\/JAK 2 mutation linked with the myeloproliferative disorders","volume":"19","author":"Smira","year":"2010","journal-title":"J Gastrointest Liver Dis"},{"key":"10.1111\/jth.12265_bb0255","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1111\/j.1365-2036.2010.04299.x","article-title":"The prevalence of the activating JAK2 tyrosine kinase mutation in chronic porto\u2010splenomesenteric venous thrombosis","volume":"31","author":"Orr","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1111\/jth.12265_bb0260","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/hep.23259","article-title":"Acute portal vein thrombosis unrelated to cirrhosis: a prospective multicenter follow\u2010up study","volume":"51","author":"Plessier","year":"2010","journal-title":"Hepatology"},{"key":"10.1111\/jth.12265_bb0265","first-page":"429","article-title":"JAK2 mutation in patients with splanchnic venous thrombosis: a pilot study from India","volume":"135","author":"Sazawal","year":"2012","journal-title":"Indian J Med Res"},{"key":"10.1111\/jth.12265_bb0270","doi-asserted-by":"crossref","first-page":"4921","DOI":"10.1182\/blood-2011-09-376517","article-title":"Myeloproliferative neoplasms in Budd\u2013Chiari syndrome and portal vein thrombosis: a meta\u2010analysis","volume":"120","author":"Smalberg","year":"2012","journal-title":"Blood"},{"key":"10.1111\/jth.12265_bb0275","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1111\/j.1538-7836.2009.03354.x","article-title":"JAK2\u2010V617F mutation in cerebral venous thrombosis","volume":"7","author":"Koopman","year":"2009","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.12265_bb0280","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1111\/j.1538-7836.2012.04719.x","article-title":"The JAK2 V617F mutation in patients with cerebral venous thrombosis","volume":"10","author":"Passamonti","year":"2012","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.12265_bb0285","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1160\/TH08-02-0081","article-title":"The V617F JAK\u00a02 mutation is not a frequent event in patients with cerebral venous thrombosis without overt chronic myeloproliferative disorder","volume":"99","author":"Bellucci","year":"2008","journal-title":"Thromb Haemost"},{"key":"10.1111\/jth.12265_bb0290","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1097\/MBC.0b013e328304e0a9","article-title":"Low prevalence of the JAK2V617F in patients with ischemic stroke or cerebral venous thrombosis","volume":"19","author":"Xavier","year":"2008","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1111\/jth.12265_bb0295","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.jns.2012.09.012","article-title":"Janus kinase (JAK)\u00a02 V617F mutation in Asian Indians with cerebral venous thrombosis and without overt myeloproliferative disorders","volume":"323","author":"De","year":"2012","journal-title":"J Neurol Sci"},{"key":"10.1111\/jth.12265_bb0300","doi-asserted-by":"crossref","first-page":"4105","DOI":"10.1182\/blood-2007-01-066985","article-title":"The interaction between leukocytosis and other risk factors for thrombosis in essential thrombocythemia","volume":"109","author":"Tefferi","year":"2007","journal-title":"Blood"},{"key":"10.1111\/jth.12265_bb0305","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1007\/s002770000244","article-title":"The predictive value of vascular risk factors and gender for the development of thrombotic complications in essential thrombocythemia","volume":"80","author":"Jantunen","year":"2001","journal-title":"Ann Hematol"},{"key":"10.1111\/jth.12265_bb0310","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1177\/107602960000600105","article-title":"Essential thrombocythemia in young adults: major thrombotic complications and complications during pregnancy \u2013 a follow\u2010up study in 68 patients","volume":"6","author":"Randi","year":"2000","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1111\/jth.12265_bb0315","doi-asserted-by":"crossref","first-page":"5128","DOI":"10.1182\/blood-2012-07-444067","article-title":"Development and validation of an International Prognostic Score of thrombosis in World Health Organization\u2010essential thrombocythemia (IPSET\u2010thrombosis)","volume":"120","author":"Barbui","year":"2012","journal-title":"Blood"},{"key":"10.1111\/jth.12265_bb0320","doi-asserted-by":"crossref","first-page":"331","DOI":"10.3324\/haematol.12604","article-title":"Prevention of thrombosis in polycythemia vera and essential thrombocythemia","volume":"93","author":"Landolfi","year":"2008","journal-title":"Haematologica"},{"key":"10.1111\/jth.12265_bb0325","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1111\/j.1365-2141.2011.08903.x","article-title":"Very elderly patients with essential thrombocythaemia: are they a separate category? A monocentric study on 118 patients older than 75\u00a0years","volume":"156","author":"Palandri","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1111\/jth.12265_bb0330","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.3324\/haematol.2010.025064","article-title":"Thrombosis in myelofibrosis: prior thrombosis is the only predictive factor and most venous events are provoked","volume":"95","author":"Elliott","year":"2010","journal-title":"Haematologica"},{"key":"10.1111\/jth.12265_bb0335","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1002\/cncr.21891","article-title":"Estrogen\u2010based hormone therapy and thrombosis risk in women with essential thrombocythemia","volume":"106","author":"Gangat","year":"2006","journal-title":"Cancer"},{"key":"10.1111\/jth.12265_bb0340","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1038\/leu.2008.253","article-title":"Thrombosis in myeloproliferative disorders: pathogenetic facts and speculation","volume":"22","author":"Landolfi","year":"2008","journal-title":"Leukemia"},{"key":"10.1111\/jth.12265_bb0345","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1200\/JCO.2010.31.8436","article-title":"Philadelphia\u2010negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet","volume":"29","author":"Barbui","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1111\/jth.12265_bb0350","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1016\/S0140-6736(05)67785-9","article-title":"Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study","volume":"366","author":"Campbell","year":"2005","journal-title":"Lancet"},{"key":"10.1111\/jth.12265_bb0355","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1038\/leu.2008.113","article-title":"Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal","volume":"22","author":"Vannucchi","year":"2008","journal-title":"Leukemia"},{"key":"10.1111\/jth.12265_bb0360","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1038\/sj.leu.2403902","article-title":"Clinical implications of the JAK2 V617F mutation in essential thrombocythemia","volume":"19","author":"Antonioli","year":"2005","journal-title":"Leukemia"},{"key":"10.1111\/jth.12265_bb0365","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/cncr.21645","article-title":"The clinical phenotype of wild\u2010type, heterozygous, and homozygous JAK2V617F in polycythemia vera","volume":"106","author":"Tefferi","year":"2006","journal-title":"Cancer"},{"key":"10.1111\/jth.12265_bb0370","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3324\/haematol.10634","article-title":"Risk of thrombosis in patients with essential thrombocythemia and polycythemia vera according to JAK2 V617F mutation status","volume":"92","author":"Finazzi","year":"2007","journal-title":"Haematologica"},{"key":"10.1111\/jth.12265_bb0375","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1038\/sj.leu.2404854","article-title":"Prospective identification of high\u2010risk polycythemia vera patients based on JAK2(V617F) allele burden","volume":"21","author":"Vannucchi","year":"2007","journal-title":"Leukemia"},{"key":"10.1111\/jth.12265_bb0380","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1038\/leu.2010.148","article-title":"A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications","volume":"24","author":"Passamonti","year":"2010","journal-title":"Leukemia"},{"key":"10.1111\/jth.12265_bb0385","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.thromres.2009.02.004","article-title":"Association of V617F Jak2 mutation with the risk of thrombosis among patients with essential thrombocythaemia or idiopathic myelofibrosis: a systematic review","volume":"124","author":"Lussana","year":"2009","journal-title":"Thromb Res"},{"key":"10.1111\/jth.12265_bb0390","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/j.exphem.2009.06.006","article-title":"JAK2V617F allele burden and thrombosis: a direct comparison in essential thrombocythemia and polycythemia vera","volume":"37","author":"Carobbio","year":"2009","journal-title":"Exp Hematol"},{"key":"10.1111\/jth.12265_bb0395","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s00277-009-0788-5","article-title":"Increased risk of recurrent thrombosis in patients with essential thrombocythemia carrying the homozygous JAK2 V617F mutation","volume":"89","author":"De Stefano","year":"2010","journal-title":"Ann Hematol"},{"key":"10.1111\/jth.12265_bb0400","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1182\/blood-2010-11-316810","article-title":"Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon\u00a012 mutations","volume":"117","author":"Passamonti","year":"2011","journal-title":"Blood"},{"key":"10.1111\/jth.12265_bb0405","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1182\/blood-2008-01-135897","article-title":"Characteristics and clinical correlates of MPL 515W>L\/K mutation in essential thrombocythemia","volume":"112","author":"Vannucchi","year":"2008","journal-title":"Blood"},{"key":"10.1111\/jth.12265_bb0410","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1208500","article-title":"Cardiovascular events and intensity of treatment in polycythemia vera","volume":"368","author":"Marchioli","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.12265_bb0415","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1182\/blood-2012-04-424911","article-title":"Correlation of blood counts with vascular complications in essential thrombocythemia: analysis of the prospective PT1 cohort","volume":"120","author":"Campbell","year":"2012","journal-title":"Blood"},{"key":"10.1111\/jth.12265_bb0420","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1038\/leu.2011.258","article-title":"Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria","volume":"26","author":"Finazzi","year":"2012","journal-title":"Leukemia"},{"key":"10.1111\/jth.12265_bb0425","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/j.1600-0609.2010.01548.x","article-title":"The impact of peripheral blood values and bone marrow findings on prognosis for patients with essential thrombocythemia and polycythemia vera","volume":"86","author":"Abdulkarim","year":"2011","journal-title":"Eur J Haematol"},{"key":"10.1111\/jth.12265_bb0430","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1182\/blood-2011-11-393819","article-title":"Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcome","volume":"119","author":"Barbui","year":"2012","journal-title":"Blood"},{"key":"10.1111\/jth.12265_bb0435","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1002\/ajh.23295","article-title":"Plasma cytokines in polycythemia vera: phenotypic correlates, prognostic relevance, and comparison with myelofibrosis","volume":"87","author":"Vaidya","year":"2012","journal-title":"Am J Hematol"},{"key":"10.1111\/jth.12265_bb0440","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1182\/blood.V91.4.1288","article-title":"Correlation of thrombosis with increased platelet turnover in thrombocytosis","volume":"91","author":"Rinder","year":"1998","journal-title":"Blood"},{"key":"10.1111\/jth.12265_bb0445","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1182\/blood-2011-02-339655","article-title":"JAK2V617F mutation and hydroxyurea treatment as determinants of immature platelet parameters in essential thrombocythemia and polycythemia vera patients","volume":"118","author":"Panova\u2010Noeva","year":"2011","journal-title":"Blood"},{"key":"10.1111\/jth.12265_bb0450","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1182\/blood-2007-11-123091","article-title":"Circulating endothelial progenitor cells and residual in\u00a0vivo thromboxane biosynthesis in low\u2010dose aspirin\u2010treated polycythemia vera patients","volume":"112","author":"Santilli","year":"2008","journal-title":"Blood"},{"key":"10.1111\/jth.12265_bb0455","doi-asserted-by":"crossref","first-page":"3359","DOI":"10.1182\/blood-2011-02-337337","article-title":"Clearance of circulating activated platelets in polycythemia vera and essential thrombocythemia","volume":"118","author":"Maugeri","year":"2011","journal-title":"Blood"},{"key":"10.1111\/jth.12265_bb0460","doi-asserted-by":"crossref","first-page":"315","DOI":"10.3324\/haematol.2010.031070","article-title":"Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C\u2010reactive protein and pentraxin\u00a03","volume":"96","author":"Barbui","year":"2011","journal-title":"Haematologica"},{"key":"10.1111\/jth.12265_bb0465","doi-asserted-by":"crossref","first-page":"3595","DOI":"10.1182\/blood-2011-06-359224","article-title":"Aspirin\u2010insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target","volume":"119","author":"Pascale","year":"2012","journal-title":"Blood"},{"key":"10.1111\/jth.12265_bb0470","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1182\/asheducation.V2012.1.571.3798557","article-title":"Thrombotic disease in the myeloproliferative neoplasms","volume":"2012","author":"Falanga","year":"2012","journal-title":"Hematology\/the Education Program of the American Society of Hematology"},{"key":"10.1111\/jth.12265_bb0475","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/j.1365-2141.2006.06430.x","article-title":"The haematocrit and platelet target in polycythemia vera","volume":"136","author":"Di Nisio","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1111\/jth.12265_bb0480","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1056\/NEJM198005013021803","article-title":"Erythrocyte adherence to endothelium in sickle\u2010cell anemia. A possible determinant of disease severity","volume":"302","author":"Hebbel","year":"1980","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.12265_bb0485","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1056\/NEJM198107303050501","article-title":"Increased adhesion of erythrocytes to endothelial cells in diabetes mellitus and its relation to vascular complications","volume":"305","author":"Wautier","year":"1981","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.12265_bb0490","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1182\/blood-2006-10-048298","article-title":"Increased adhesion to endothelial cells of erythrocytes from patients with polycythemia vera is mediated by laminin alpha5 chain and Lu\/BCAM","volume":"110","author":"Wautier","year":"2007","journal-title":"Blood"},{"key":"10.1111\/jth.12265_bb0495","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1160\/TH09-09-0663","article-title":"Nitric oxide derivatives and soluble plasma selectins in patients with myeloproliferative neoplasms","volume":"104","author":"Cella","year":"2010","journal-title":"Thromb Haemost"},{"key":"10.1111\/jth.12265_bb0500","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1182\/blood-2012-07-440487","article-title":"JAK2V617F activates Lu\/BCAM\u2010mediated red cell adhesion in polycythemia vera through an EpoR\u2010independent Rap1\/Akt pathway","volume":"121","author":"De Grandis","year":"2013","journal-title":"Blood"},{"key":"10.1111\/jth.12265_bb0505","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.cyto.2010.04.011","article-title":"Monocyte IL\u20102Ralpha expression is associated with thrombosis and the JAK2V617F mutation in myeloproliferative neoplasms","volume":"51","author":"Goette","year":"2010","journal-title":"Cytokine"},{"key":"10.1111\/jth.12265_bb0510","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/nrmicro1710","article-title":"Beneficial suicide: why neutrophils die to make NETs","volume":"5","author":"Brinkmann","year":"2007","journal-title":"Nat Rev Microbiol"},{"key":"10.1111\/jth.12265_bb0515","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1182\/blood-2011-03-343061","article-title":"Extracellular histones promote thrombin generation through platelet\u2010dependent mechanisms: involvement of platelet TLR2 and TLR4","volume":"118","author":"Semeraro","year":"2011","journal-title":"Blood"},{"key":"10.1111\/jth.12265_bb0520","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/j.1538-7836.2011.04544.x","article-title":"Neutrophil extracellular traps promote deep vein thrombosis in mice","volume":"10","author":"Brill","year":"2012","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.12265_bb0525","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1046\/j.1365-2141.2000.02030.x","article-title":"Increased platelet activation and abnormal membrane glycoprotein content and redistribution in myeloproliferative disorders","volume":"110","author":"Jensen","year":"2000","journal-title":"Br J Haematol"},{"key":"10.1111\/jth.12265_bb0530","first-page":"169","article-title":"Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status","volume":"91","author":"Arellano\u2010Rodrigo","year":"2006","journal-title":"Haematologica"},{"key":"10.1111\/jth.12265_bb0535","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1056\/NEJMoa035572","article-title":"Efficacy and safety of low\u2010dose aspirin in polycythemia vera","volume":"350","author":"Landolfi","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.12265_bb0540","doi-asserted-by":"crossref","first-page":"4061","DOI":"10.1182\/blood-2008-06-164087","article-title":"Thrombin generation and activated protein\u00a0C resistance in patients with essential thrombocythemia and polycythemia vera","volume":"112","author":"Marchetti","year":"2008","journal-title":"Blood"},{"key":"10.1111\/jth.12265_bb0545","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.bcmd.2011.01.003","article-title":"Polymorphonuclear neutrophils from JAK2(V617F) positive MPD patients do not support hypercoagulability: a study with calibrated automated thrombography (CAT)","volume":"46","author":"Perrin","year":"2011","journal-title":"Blood Cells Mol Dis"},{"key":"10.1111\/jth.12265_bb0550","doi-asserted-by":"crossref","first-page":"5246","DOI":"10.1182\/blood-2008-11-191544","article-title":"The presence of JAK2V617F mutation in the liver endothelial cells of patients with Budd\u2013Chiari syndrome","volume":"113","author":"Sozer","year":"2009","journal-title":"Blood"},{"key":"10.1111\/jth.12265_bb0555","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/ajh.23135","article-title":"Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management","volume":"87","author":"Tefferi","year":"2012","journal-title":"Am J Hematol"},{"key":"10.1111\/jth.12265_bb0560","first-page":"132","article-title":"Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols","volume":"23","author":"Berk","year":"1986","journal-title":"Semin Hematol"},{"key":"10.1111\/jth.12265_bb0565","doi-asserted-by":"crossref","first-page":"3370","DOI":"10.1182\/blood.V90.9.3370","article-title":"Treatment of polycythemia vera: the use of hydroxyurea and pipobroman in 292 patients under the age of 65\u00a0years","volume":"90","author":"Najean","year":"1997","journal-title":"Blood"},{"key":"10.1111\/jth.12265_bb0570","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/bjc.1981.150","article-title":"Treatment of polycythaemia vera by radiophosphorus or busulphan: a randomized trial","volume":"44","author":"Haanen","year":"1981","journal-title":"Br J Cancer"},{"key":"10.1111\/jth.12265_bb0575","first-page":"17","article-title":"From efficacy to safety: a Polycythemia Vera Study Group report on hydroxyurea in patients with polycythemia vera","volume":"34","author":"Fruchtman","year":"1997","journal-title":"Semin Hematol"},{"key":"10.1111\/jth.12265_bb0580","doi-asserted-by":"crossref","first-page":"3907","DOI":"10.1200\/JCO.2011.36.0792","article-title":"Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980","volume":"29","author":"Kiladjian","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1111\/jth.12265_bb0585","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1182\/blood-2011-10-387787","article-title":"Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera","volume":"119","author":"Alvarez\u2010Larran","year":"2012","journal-title":"Blood"},{"key":"10.1111\/jth.12265_bb0590","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1182\/blood-2008-03-143537","article-title":"Pegylated interferon\u2010alfa\u20102a induces complete hematologic and molecular responses with low toxicity in polycythemia vera","volume":"112","author":"Kiladjian","year":"2008","journal-title":"Blood"},{"key":"10.1111\/jth.12265_bb0595","doi-asserted-by":"crossref","first-page":"5418","DOI":"10.1200\/JCO.2009.23.6075","article-title":"Pegylated interferon alfa\u20102a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera","volume":"27","author":"Quintas\u2010Cardama","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1111\/jth.12265_bb0600","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJM199504273321704","article-title":"Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis","volume":"332","author":"Cortelazzo","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.12265_bb0605","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa043800","article-title":"Hydroxyurea compared with anagrelide in high\u2010risk essential thrombocythemia","volume":"353","author":"Harrison","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.12265_bb0610","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1182\/blood-2006-05-025544","article-title":"Management of extreme thrombocytosis in otherwise low\u2010risk essential thrombocythemia; does number matter?","volume":"108","author":"Tefferi","year":"2006","journal-title":"Blood"},{"key":"10.1111\/jth.12265_bb0615","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1182\/blood-2006-09-046342","article-title":"Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status","volume":"109","author":"Carobbio","year":"2007","journal-title":"Blood"},{"key":"10.1111\/jth.12265_bb0620","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.leukres.2010.10.009","article-title":"Aspirin in low\u2010risk essential thrombocythemia, not so simple after all?","volume":"35","author":"Harrison","year":"2011","journal-title":"Leuk Res"},{"key":"10.1111\/jth.12265_bb0625","first-page":"CD006503","article-title":"Antiplatelet drugs for polycythaemia vera and essential thrombocythaemia","volume":"4","author":"Squizzato","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1111\/jth.12265_bb0630","first-page":"1748","article-title":"How epidemiology of polycythemia vera has changed in the last 10\u00a0years: results from the whole prospective cohort of patients in CYTO\u2010PV trial as compared with ECLAP prospective cohort","volume":"120","author":"Masciulli","year":"2012","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1111\/jth.12265_bb0635","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.hoc.2011.01.008","article-title":"Myeloproliferative disorders in pregnancy","volume":"25","author":"Harrison","year":"2011","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1111\/jth.12265_bb0640","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1182\/blood-2007-07-102665","article-title":"Postsurgery outcomes in patients with polycythemia vera and essential thrombocythemia: a retrospective survey","volume":"111","author":"Ruggeri","year":"2008","journal-title":"Blood"},{"key":"10.1111\/jth.12265_bb0645","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/j.1365-2141.2005.05400.x","article-title":"Pregnancy and its management in the Philadelphia negative myeloproliferative diseases","volume":"129","author":"Harrison","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1111\/jth.12265_bb0650","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1111\/j.1538-7836.2011.04484.x","article-title":"Long\u2010term follow\u2010up of patients with portal vein thrombosis and myeloproliferative neoplasms","volume":"9","author":"Hoekstra","year":"2011","journal-title":"J Thromb Haemost"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjth.12265","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjth.12265","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S153878362213583X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S153878362213583X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/jth.12265\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T03:05:48Z","timestamp":1761534348000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S153878362213583X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7]]},"references-count":129,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2013,7]]}},"alternative-id":["S153878362213583X"],"URL":"https:\/\/doi.org\/10.1111\/jth.12265","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.718002151.793483108","asserted-by":"object"}]},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2013,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Thrombotic complications of myeloproliferative neoplasms: risk assessment and risk\u2010guided management","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/jth.12265","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}